Drug intelligence / Profile preview

MBX-701

Development stage: Discontinued
Lead developer: Microbiotix
Modality: Small Molecules

Overview

MBX-701 is a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, initially developed by Merck & Co., Inc. and later by Microbiotix, Inc. as part of a combination with MBX-700. It targets the NS5B enzyme essential for HCV viral replication, representing an investigational antiviral agent for chronic hepatitis C treatment. Development has been discontinued globally.[5][7]

Other names: SCH 900188SCH900188SCH-900188

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on MBX-701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBX-701.

Explore the full profile